Takeshita Akihiro, Naito Kensuke, Ohno Ryuzo
Laboratory Medicine, Hamamatsu University School of Medicine.
Nihon Rinsho. 2002 Mar;60(3):517-24.
Recently, monoclonal antibody(MoAb) therapies which direct at antigens such as CD33, CD45 and GM-CSF receptors on myeloid leukemia cells have been in progress. There are three major MoAb therapies against acute myeloid leukemia(AML), which include unconjugated MoAb, MoAb conjugated with chemotherapy or toxins, and MoAb conjugated with radioisotopes. Gemtuzumab ozogamicin is consisting of an engineered human anti-CD33 antibody linked with the potent anti-tumor antibiotic calicheamicin, which is the most effective for AML. However, recent studies suggested that calicheamicin was also pumped out by multi-drug resistance(MDR) related P-glycoprotein. The combination therapy with MDR modifiers may improve the effect of gemtuzumab ozogamicin.
最近，针对髓系白血病细胞上诸如CD33、CD45和GM-CSF受体等抗原的单克隆抗体（MoAb）疗法一直在进行中。有三种主要的针对急性髓系白血病（AML）的单克隆抗体疗法，包括未偶联的单克隆抗体、与化疗药物或毒素偶联的单克隆抗体以及与放射性同位素偶联的单克隆抗体。吉妥单抗由一种经过工程改造的人抗CD33抗体与强效抗肿瘤抗生素卡奇霉素连接而成，它对AML最为有效。然而，最近的研究表明，卡奇霉素也会被多药耐药（MDR）相关的P-糖蛋白泵出。与MDR调节剂的联合疗法可能会提高吉妥单抗的疗效。
